Posts Tagged casodex bicalutamide
Commercial Insight: Antihormonal Cancer Therapies – Leading brands strive to minimize generic sales erosion now available at ReportsandReports
Introduction
Antihormonal cancer therapies are a class of drugs used predominantly in the treatment of breast cancer and prostate cancer. The high incidence of these tumor types translates into a significant commercial potential for drug developers. Collectively, the antihormonal therapy cancer brands generated sales of about .0 billion in the seven major pharmaceutical markets in 2009.
Scope
Topic: bicalutamide, brand presence, breast cancer, cancer therapies, casodex bicalutamide, key success factors, leuprolide, pharmaceutical markets, treatment of breast cancer, tumor typesRelated Topic
Prostate Cancer – Germany Drug Forecasts and Treatment Analysis to 2020
GlobalData analysis finds that the prostate cancer therapeutics market in Germany is attractive and is primarily driven by the growth in the hormone-refractory prostate cancer therapeutics market. The growth in the number of total patients receiving treatment and increase in the annual cost of hormone-refractory prostate cancer therapy is expected to offset the impact of generic erosion in hormone-dependent prostate cancer therapy. The patient volume was driven by growth in treatment usage patterns such as diseased population, treatment seeking population, diagnosis population and prescription population. The annual cost of prostate cancer therapy between 2001 and 2009 was driven by increased uptake of chemotherapy using Taxotere. Expected launch of new therapies such as Provenge (sipuleucel-T) and Jevtana (cabazitaxel) will further drive the annual cost of therapy.
Hormone therapy using combination of hormone therapies such as LHRH agonists and androgen receptor antagonists is a prominent treatment regime. Taxotere is the current standard of care for patients that stop responding to hormone therapy. The introduction of new therapies for metastatic prostate cancer is expected to expand the market further.
Topic: androgen receptor, cancer therapeutics, casodex bicalutamide, hormone refractory prostate cancer, hormone therapies, prostate cancer, prostate cancer therapy, receptor antagonists, refractory prostate cancer, treatment regimeRelated Topic